SCHEMBL856762

SCHEMBL856762

CS(=O)(=O)c1cccc(-c2cc(N3CCOCC3)nc(Cl)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 9/20 0.52
PIK3CG P48736 2/20 0.52
ATR Q13535 3/20 0.49
ATRIP Q8WXE1 1/20 0.49
HSD17B10 Q99714 3/20 0.49
MAPT P10636 2/20 0.49
TSHR P16473 2/20 0.49
MAPK1 P28482 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RAF1 P04049 1/20 0.47
BRAF P15056 1/20 0.47
JAK2 O60674 2/20 0.46
JAK3 P52333 2/20 0.46
PTK2 Q05397 1/20 0.46
MTOR P42345 2/20 0.46
AKT1 P31749 2/20 0.45
ALDH1A1 P00352 3/20 0.45
USP2 O75604 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451481 0.80 NPSR1 (0.74) PIK3CAPIK3CGHSD17B10MAPTTSHR
SCHEMBL855549 0.80 MEN1 (0.52) ATRMAPTJAK2ALDH1A1HPGD
SCHEMBL1263031 0.80 MAPT (0.54) PIK3CAPIK3CGATRATRIPHSD17B10
SCHEMBL1263673 0.77 MAPK1 (0.53) PIK3CAPIK3CGHSD17B10MAPTTSHR
SCHEMBL2724756 0.76 PIK3CA (0.51) PIK3CAPIK3CGATRATRIPTSHR
SCHEMBL857685 0.76 CTSS (0.48) ATRMAPTJAK2ALDH1A1HPGD
SCHEMBL855781 0.75 PIK3CA (0.57) PIK3CAPIK3CGMTORAKT1PIK3CB
SCHEMBL855455 0.75 PIK3CA (0.65) PIK3CAPIK3CGMTORAKT1PIK3CB
SCHEMBL3450481 0.75 ABL1 (0.55) PIK3CAPIK3CGRAF1BRAFJAK2
SCHEMBL3994331 0.74 PIK3CA (0.58) PIK3CAPIK3CGMTORAKT1PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173647-B2 PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-08 US disclosed
US-8173647-B2 PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-05-08 US disclosed
EP-2118087-B1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-03-28 EP disclosed
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2010-02-25 US disclosed
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2010-02-25 US disclosed
EP-2118087-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE Novartis Ag (CH) 2009-11-18 EP disclosed
WO-2008098058-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048547-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE PI4KA, PI4KB, PI4K2A PIK3CA 5/4885PIK3CG 9/4885ATR 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.